A Phase 2 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Ascending Dose Study of SB206 in Subjects With Molluscum Contagiosum
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2018
At a glance
- Drugs Nitric oxide (Primary)
- Indications Molluscum contagiosum
- Focus Therapeutic Use
- Sponsors Novan Inc
- 10 Dec 2018 Primary endpoint (Proportion of Subjects Achieving Complete Clearance at Week 12) has been met, according to a Novan Inc media release.
- 10 Dec 2018 Results presented in the Novan Inc media release.
- 03 Dec 2018 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History